Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

419 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension-A randomized, open-label, active-controlled, superiority, parallel-group clinical trial.
Hwang YC, Yoon KH, Cha BS, Lee KW, Jang HC, Min KW, Chung CH, Lee MK. Hwang YC, et al. Among authors: min kw. Int J Clin Pract. 2017 Sep;71(9):e12987. doi: 10.1111/ijcp.12987. Epub 2017 Aug 24. Int J Clin Pract. 2017. PMID: 28840637 Free PMC article. Clinical Trial.
A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.
Rhee EJ, Lee WY, Yoon KH, Yoo SJ, Lee IK, Baik SH, Kim YK, Lee MK, Park KS, Park JY, Cha BS, Lee HW, Min KW, Bae HY, Kim MJ, Kim JA, Kim DK, Kim SW. Rhee EJ, et al. Among authors: min kw. Diabetes Obes Metab. 2010 Dec;12(12):1113-9. doi: 10.1111/j.1463-1326.2010.01303.x. Diabetes Obes Metab. 2010. PMID: 20977584 Clinical Trial.
Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).
Seino Y, Min KW, Niemoeller E, Takami A; EFC10887 GETGOAL-L Asia Study Investigators. Seino Y, et al. Among authors: min kw. Diabetes Obes Metab. 2012 Oct;14(10):910-7. doi: 10.1111/j.1463-1326.2012.01618.x. Epub 2012 May 30. Diabetes Obes Metab. 2012. PMID: 22564709 Free PMC article. Clinical Trial.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Rhee EJ, Lee WY, Min KW, Shivane VK, Sosale AR, Jang HC, Chung CH, Nam-Goong IS, Kim JA, Kim SW; Gemigliptin Study 006 Group. Rhee EJ, et al. Among authors: min kw. Diabetes Obes Metab. 2013 Jun;15(6):523-30. doi: 10.1111/dom.12060. Epub 2013 Jan 30. Diabetes Obes Metab. 2013. PMID: 23320436 Clinical Trial.
Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes.
Hwang YC, Kang M, Ahn CW, Park JS, Baik SH, Chung DJ, Jang HC, Kim KA, Lee IK, Min KW, Nam M, Park TS, Son SM, Sung YA, Woo JT, Park KS, Lee MK. Hwang YC, et al. Among authors: min kw. Int J Clin Pract. 2013 Mar;67(3):236-43. doi: 10.1111/ijcp.12071. Epub 2013 Jan 22. Int J Clin Pract. 2013. PMID: 23336668 Clinical Trial.
A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise.
Jung CH, Park CY, Ahn KJ, Kim NH, Jang HC, Lee MK, Park JY, Chung CH, Min KW, Sung YA, Park JH, Kim SJ, Lee HJ, Park SW. Jung CH, et al. Among authors: min kw. Diabetes Metab Res Rev. 2015 Mar;31(3):295-306. doi: 10.1002/dmrr.2613. Epub 2014 Dec 5. Diabetes Metab Res Rev. 2015. PMID: 25362864 Free PMC article. Clinical Trial.
Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension.
Jin SM, Park SW, Yoon KH, Min KW, Song KH, Park KS, Park JY, Park IB, Chung CH, Baik SH, Choi SH, Lee HW, Lee IK, Kim DM, Lee MK. Jin SM, et al. Among authors: min kw. Diabetes Obes Metab. 2015 May;17(5):511-5. doi: 10.1111/dom.12429. Epub 2015 Jan 14. Diabetes Obes Metab. 2015. PMID: 25523633 Clinical Trial.
Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension.
Jin SM, Park CY, Cho YM, Ku BJ, Ahn CW, Cha BS, Min KW, Sung YA, Baik SH, Lee KW, Yoon KH, Lee MK, Park SW. Jin SM, et al. Among authors: min kw. Diabetes Obes Metab. 2015 Jun;17(6):599-602. doi: 10.1111/dom.12435. Epub 2015 Feb 8. Diabetes Obes Metab. 2015. PMID: 25580775 Free PMC article. Clinical Trial.
A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes.
Yang HK, Min KW, Park SW, Chung CH, Park KS, Choi SH, Song KH, Kim DM, Lee MK, Sung YA, Baik SH, Kim IJ, Cha BS, Park JH, Ahn YB, Lee IK, Yoo SJ, Kim J, Park IeB, Park TS, Yoon KH. Yang HK, et al. Among authors: min kw. Endocr J. 2015;62(5):449-62. doi: 10.1507/endocrj.EJ14-0544. Epub 2015 Mar 27. Endocr J. 2015. PMID: 25819061 Free article. Clinical Trial.
Basal-prandial versus premixed insulin in patients with type 2 diabetes requiring insulin intensification after basal insulin optimization: A 24-week randomized non-inferiority trial.
Jin SM, Kim JH, Min KW, Lee JH, Ahn KJ, Park JH, Jang HC, Park SW, Lee KW, Won KC, Kim YI, Chung CH, Park TS, Lee JH, Lee MK. Jin SM, et al. Among authors: min kw. J Diabetes. 2016 May;8(3):405-13. doi: 10.1111/1753-0407.12312. Epub 2015 Jun 29. J Diabetes. 2016. PMID: 25952532 Clinical Trial.
419 results